HCW Biologics is trading 10.5% lower at $1.62 amid a broader market retreat linked to higher oil prices, Treasury yields and cautious risk sentiment.
- No fresh company-specific catalyst was identified on September 23, 2026.
- Recent distribution-agreement and T-cell-engager announcements predate the decline, while biotech broadly gained; global macro pressure is the likeliest explanation.